These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11338324)

  • 1. Prevention research and its actual application to health services.
    Holder HD
    J Behav Health Serv Res; 2001 May; 28(2):118-29. PubMed ID: 11338324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priorities among recommended clinical preventive services.
    Coffield AB; Maciosek MV; McGinnis JM; Harris JR; Caldwell MB; Teutsch SM; Atkins D; Richland JH; Haddix A
    Am J Prev Med; 2001 Jul; 21(1):1-9. PubMed ID: 11418251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of prevention: experiences of a public health agency.
    Corso PS; Thacker SB; Koplan JP
    Med Decis Making; 2002; 22(5 Suppl):S11-6. PubMed ID: 12369226
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing prevention effectiveness using data to drive program decisions.
    Thacker SB; Koplan JP; Taylor WR; Hinman AR; Katz MF; Roper WL
    Public Health Rep; 1994; 109(2):187-94. PubMed ID: 8153269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The "Intervention Index": insufficient information.
    Kottke TE
    J Clin Epidemiol; 1992 Jan; 45(1):17-9. PubMed ID: 1738007
    [No Abstract]   [Full Text] [Related]  

  • 6. Methods for priority setting among clinical preventive services.
    Maciosek MV; Coffield AB; McGinnis JM; Harris JR; Caldwell MB; Teutsch SM; Atkins D; Richland JH; Haddix A
    Am J Prev Med; 2001 Jul; 21(1):10-9. PubMed ID: 11418252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the effectiveness of disease and injury prevention programs: costs and consequences.
    MMWR Recomm Rep; 1995 Aug; 44(RR-10):1-10. PubMed ID: 7565538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of health services research in the treatment and prevention of alcohol abuse. Introduction.
    McCarty D; Weisner C; Huebner RB
    J Behav Health Serv Res; 2001 May; 28(2):115-7. PubMed ID: 11338323
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN.
    Finkelstein EA; Wittenborn JS; Farris RP
    J Womens Health (Larchmt); 2004 Jun; 13(5):625-33. PubMed ID: 15257854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allocating HIV-prevention resources: balancing efficiency and equity.
    Kaplan EH; Merson MH
    Am J Public Health; 2002 Dec; 92(12):1905-7. PubMed ID: 12453805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective treatments for substance abuse: avoid throwing the baby out with the bath water.
    Peele S; Brodsky A
    Med Interface; 1994 Feb; 7(2):78-9, 82-4. PubMed ID: 10132449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of methodological practices in the evaluation of alcohol and other drug (AOD) abuse prevention.
    Brounstein PJ; Emshoff JG; Hill GA; Stoil MJ
    J Health Soc Policy; 1997; 9(2):1-19. PubMed ID: 10174375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling prevention program effects on growth in substance use: analysis of five years of data from the Adolescent Alcohol Prevention Trial.
    Taylor BJ; Graham JW; Cumsille P; Hansen WB
    Prev Sci; 2000 Dec; 1(4):183-97. PubMed ID: 11523747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of resource allocation models in selecting clinical preventive services.
    Wang LY; Haddix AC; Teutsch SM; Caldwell B
    Am J Manag Care; 1999 Apr; 5(4):445-54. PubMed ID: 10387384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    Holtgrave DR
    J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative policy analysis and public health policy: a macro and micro view.
    Hinman AR
    Am J Prev Med; 1997; 13(1):6-11. PubMed ID: 9037336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of drug abuse treatment for primary prevention of acquired immunodeficiency syndrome: epidemiologic considerations.
    Lampinen TM
    NIDA Res Monogr; 1991; 113():114-28. PubMed ID: 1762635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A framework for assessing the effectiveness of disease and injury prevention.
    Teutsch SM
    MMWR Recomm Rep; 1992 Mar; 41(RR-3):1-12. PubMed ID: 1313535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.